title: Nadir neutrophil counts in patients treated for breast cancer with doxorubicin and cyclophosphamide.
abstract: OBJECTIVE
  To determine the impact on neutrophils if adriamycin is administered at 60 mg/m2 and cyclophosphamide at 600/m2 (AC 60/600); and at 50 mg/m2 and 500 mg/m2 (50/500) in the treatment of breast cancer.
  
  
  METHODS
  Restrospective analysis of nadir neutrophil counts in female mammary carcinoma patients treated with adriamycin/cyclophosphamide combination.
  
  
  METHODS
  Hurlingham Oncology Clinic, Nairobi and The Nairobi Hospital between March 1995 and August 1999.
  
  
  METHODS
  Eighteen patients with breast cancer were treated either for adjuvant purposes or for metastatic disease.
  
  
  METHODS
  Chemotherapy with adriamycin and cyclophosphamide at 60/600 or 50/500. Patients were advised to avoid crowded places and given prophylactic broadspectrum antibiotics whenever grade 4 neutropenia occurred at nadir.
  
  
  RESULTS
  Grade 3-4 neutropenia occurred in 75.5% of treatments at 60/600 and in 56.8% of the treatments at 50/500. Febrile neutropenia followed only one treatment and did not result in death.
  
  
  CONCLUSIONS
  Neutropenia is frequent and severe at A/C 60/600 and need to be watched out for. Sepsis on the other hand is prevented if meticulous attention is given and corrective measures taken. A/C 50/500 was associated with less occurrences of neutropenia though still very high. Neutropenia should therefore be checked and steps be taken to prevent sepsis even at this dosage.
authors.affiliation: Department of Medicine, Faculty of Medicine, College of Health Sciences, University of Nairobi, P.O. Box 19676, Nairobi.
authors.forename: N A
authors.initials: NA
authors.lastname: Othieno-Abinya
authors.forename: L O
authors.initials: LO
authors.lastname: Nyabola
authors.forename: A O
authors.initials: AO
authors.lastname: Nyong'o
authors.forename: R
authors.initials: R
authors.lastname: Baraza
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009504:Neutrophils / Q000166:cytology*; D012189:Retrospective Studies
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide